![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.biospace.com/article/releases/wize-pharma-receives-bonus-biogroup-shares-from-escrow-and-additional-bonus-biogroup-shares-totaling-1-3-million/?s=79
https://www.prnewswire.com/news-releases/wize-pharma-receives-bonus-biogroup-shares-from-escrow-and-additional-bonus-biogroup-shares-totaling-1-3-million-301200230.html
https://www.prnewswire.com/news-releases/wize-pharma-and-cosmos-capital-enter-into-bid-implementation-agreement-301199333.html
https://www.prnewswire.com/news-releases/wize-pharma-announces-positive-topline-results-in-phase-iv-study-of-lo2a-for-the-treatment-of-dry-eye-syndrome-in-patients-with-sjogrens-syndrome-301171988.html
https://www.prnewswire.com/il/news-releases/wize-pharmas-strategic-transaction-partner-bonus-biogroup-to-present-mesencure-data-at-the-international-society-for-cell--gene-therapy-isct-annual-meeting-on-may-28-29-2020-301066108.html
https://www.prnewswire.com/news-releases/wize-pharmas-strategic-transaction-partner-bonus-biogroup-reports-successful-treatment-of-acute-pneumonia-in-preclinical-covid-19-model-301060749.html
https://www.prnewswire.com/news-releases/wize-pharma-completes-phase-iv-study-of-lo2a-for-the-treatment-of-dry-eye-syndrome-in-patients-with-sjogrens-syndrome-301054900.html
https://www.prnewswire.com/news-releases/wize-pharmas-strategic-transaction-partner-bonus-biogroup-initiates-preclinical-study-for-treatment-of-respiratory-distress-in-covid-19-patients-301044348.html
https://www.prnewswire.com/news-releases/wize-pharma-completes-patient-enrollment-in-phase-iv-study-of-lo2a-for-the-treatment-of-dry-eye-syndrome-in-patients-with-sjogrens-syndrome-300990264.html